



(51) International Patent Classification:

A61B 5/02 (2006.01) *A61B 5/024* (2006.01)
A61B 5/00 (2006.01) *A61B 5/026* (2006.01)
A61B 5/022 (2006.01) *A61B 5/145* (2006.01)

(21) International Application Number:

PCT/US2016/040800

(22) International Filing Date:

1 July 2016 (01.07.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/187,793 1 July 2015 (01.07.2015) US

(71) Applicant: **EVERIST GENOMICS, INC.** [US/US]; 709
 W. Ellsworth Road, Ann Arbor, Michigan 48108 (US).

(72) Inventors: **LENEHAN, Peter**; 1187 Pierce Road, Chelsea,
 Michigan 48118 (US). **EVERIST, Thomas**; 973 South
 Ogdon Street, Denver, Colorado 80209 (US).

(74) Agents: **HEIMBECHER, Reed** et al.; Dykema Gossett
 PLLC, 4000 Wells Fargo Center, 90 South Seventh Street,
 Minneapolis, Minnesota 55402 (US).

(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: SYSTEM AND METHOD OF ASSESSING ENDOTHELIAL FUNCTION




FIG. 16B

(57) Abstract: A medical diagnostic system and method for assessing endothelial function comprise adjusting a reactive hyperemia indicator, measured in response to a stimulus, based on an anthropomorphic and/or demographic variable. The adjusted reactive hyperemia indicator provides a more accurate reflection of endothelial function and can be communicated to a clinician.

SYSTEM AND METHOD OF ASSESSING ENDOTHELIAL FUNCTION

INVENTORS

Peter F. Lenehan
T. Stephen Everist

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to United States provisional patent application no. 62/187,793 titled “SYSTEM AND METHOD OF ASSESSING ENDOTHELIAL FUNCTION,” filed 01 July 2015, which is hereby incorporated by reference as though fully set forth herein. This application is related to United States application no. 12/483,930, filed 12 June 2009 (the ‘980 application), now United States patent no. 8,057,400 B2, issued 15 November 2011 (the ‘400 patent). The ‘980 application and the ‘400 patent are both hereby incorporated by reference as though fully set forth herein.

FIELD

[0002] The present invention relates generally to assessing endothelial function in a mammal.

BACKGROUND

[0003] Cardiovascular disease is a leading cause of morbidity and mortality. It has been shown that the early stages of cardiovascular disease can be diagnosed by assessing the ability of the arteries to dilate in response to an increase in blood flow. The degree of arterial dilation in response to an increased blood flow correlates with the severity of cardiovascular disease.

[0004] Endothelial cells constitute the innermost lining of blood vessels and produce nitric oxide, which is the predominant vasodilator in the arterial system. An increase in blood flow results in increased shear stress at the surface of endothelial cells and initiates a signaling pathway that results in phosphorylation and activation of nitric oxide synthase, and increased production of nitric oxide. In addition to acting as a potent vasodilator, endothelium-derived nitric oxide inhibits many of the initiating steps in the pathogenesis of atherosclerotic cardiovascular disease, including low-density lipoprotein uptake, white cell adhesion to the vessel wall, vascular smooth muscle proliferation, and platelet adhesion and aggregation.

[0005] Brachial artery flow-mediated dilation serves as a measure of the bioavailability of endothelium-derived nitric oxide in patients, and it has been used extensively in large clinical studies to non-invasively detect systemic endothelial dysfunction.

[0006] Several invasive and non-invasive techniques have been developed to evaluate endothelial function. Invasive techniques, which involve intra-coronary or intra-brachial infusions of vasoactive agents, are considered to be the most accurate for the detection of endothelial dysfunction. Due to their highly invasive nature, the use of such techniques is limited and has led to the development of several non-invasive techniques. The ultrasound imaging of the brachial artery is the most commonly employed non-invasive technique for the assessment of the vasodilatory response. *See, for example, Mary C. Corretti et al. J. Am. Coll. Cardiol.* 2002; 39:257-265, which is incorporated herein by reference in its entirety. It utilizes continuous electrocardiogram (EKG) gated two-dimensional ultrasound imaging on the brachial artery before and after induction of arterial dilation by five-minute cuff

occlusion of the arm. The ultrasound imaging technique is mostly used to assess (1) the changes in the diameter of the brachial artery induced by administration of vasoactive drugs; and (2) flow-mediated dilation, which follows an occlusion of the brachial artery via inflating a cuff around the limb. Once the cuff is released, the blood flow causes shear stress on the endothelium, which, in turn, produces vasoactive substances that induce arterial dilation. The increase in the diameter of the brachial artery in healthy people is higher than that in patients with endothelial dysfunction. However, even in healthy people, the magnitude of the arterial dilation is not sufficient to be reliably determined by the ultrasound imaging technique. A trained and experienced operator is essential in obtaining meaningful data with the ultrasound imaging technique. This difficulty limits the testing of arterial dilation with the ultrasound imaging technique to specialized vascular laboratories.

[0007] Most of the existing techniques do not quantify the amount of stimulus delivered to the endothelium nor do they account for other sources of nitric oxide such as the nitric oxide transported and released by the blood cells in response to hypoxemia induced by the temporary occlusion of the brachial artery. It has been shown that these factors can significantly affect the amount of flow-mediated dilation and, therefore, inject additional variability into the test results obtained with equipment that does not account for such factors.

[0008] U.S. Patent No. 6,152,881 (to Rains et. al.), which is incorporated herein by reference in its entirety, describes a method of assessing endothelial dysfunction by determining changes in arterial volume based on measured blood pressure using a pressure cuff. The pressure cuff is held near diastolic pressure for about ten minutes after an artery occlusion until the artery returns to its normal state. The measured

pressure during this time is used to determine the endothelial function of the patient.

The extended period of applying cuff pressure to the limb affects circulation, which in turn impacts the measurements.

[0009] U.S. Pat. No. 7,390,303 (to Dafni), which is incorporated herein by reference in its entirety, describes a method of assessing arterial dilation and endothelial function, in which the relative changes in the cross sectional area of a limb artery are assessed using a bio-impedance technique to monitor cross-sectional area of a conduit artery. Measurements of bio-impedance are difficult to perform. Since bio-impedance measurements involve applying electrical to the skin of the patient, such measurements are poorly tolerated by patients due to skin irritation. Further, the measured signals vary greatly.

[0010] U.S. Patent Nos. 7,074,193 (to Satoh et al.) and 7,291,113 (to Satoh et al.) ,which are incorporated herein by reference in their entirety, describe a method and apparatus for extracting components from a measured pulse wave of blood pressure using a fourth order derivative and an n-th order derivative, respectively.

[0011] A clinical need exists for a system and method that are inexpensive, easy to perform, non-invasive, well tolerated by patients, and provide an indication of the ability arteries to respond to an increase in blood flow.

SUMMARY

[0012] Methods and diagnostic systems provide for assessing changes in arterial volume of a limb segment of a mammal and for assessing endothelial function of a mammal. In one aspect, a diagnostic system determines amplitudes of component pulse waves of detected volume pulse waves of a limb segment detected during a

baseline period to determine a baseline arterial volume of the limb segment. The diagnostic system determines amplitudes of component pulse waves of detected volume pulse waves of the limb segment detected during a time period after a stimulus has been applied to the mammal to induce a period of change in the arterial volume of the limb segment. The diagnostic system determines relative change in arterial volume of the limb segment during the time period after the stimulus relative to the arterial volume of the limb during the baseline period from the amplitudes of the component pulse waves of the detected volume pulse waves at baseline and after the stimulus.

[0013] In another aspect, the diagnostic system determines relative change in arterial volume by comparing the amplitudes of the component pulse waves of volume pulse waves at baseline and after the stimulus.

[0014] In another aspect, the component pulse wave is an early systolic component. In another aspect, the diagnostic system determines relative change in arterial volume by comparing maximum amplitudes of the early systolic components of the volume pulse waves during the baseline period and maximum amplitudes of the early systolic components of the volume pulse waves after the stimulus.

[0015] In another aspect, the diagnostic system monitors the limb segment to detect the detected volume pulse waves of the limb segment during the baseline period, and monitors the limb segment to detect the detected volume pulse waves of the limb segment during an after-stimulus period.

[0016] In another aspect, a diagnostic system applies a stimulus to generate reactive hyperemia, measures a reactive hyperemia indicator, adjusts the reactive hyperemia

indicator based on an anthropomorphic or demographic variable to arrive at an endothelial function indicator, and communicates the endothelial function indicator to a clinician.

[0017] The features and advantages described in the specification are not all inclusive and, in particular, many additional features and advantages will be apparent to one of ordinary skill in the art in view of the drawings, specification, and claims. Moreover, it should be noted that the language used in the specification has been principally selected for readability and instructional purposes, and may not have been selected to delineate or circumscribe the inventive subject matter.

BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 is a pictorial diagram illustrating a diagnostic system in accordance with the present invention.

[0019] Figure 2 is a block diagram illustrating the diagnostic system of Figure 1.

[0020] Figure 3 is a flow chart illustrating an operation of arterial volume change assessment of the diagnostic system of Figure 1.

[0021] Figure 4 is a timing diagram illustrating pressure applied to a limb during baseline testing and analysis and after-stimulus testing and analysis of Figure 3 with an occlusion providing a stimulus.

[0022] Figure 5 is a timing diagram illustrating amplitudes of early systolic components of pulse waves measured during a baseline period and an after-stimulus period of Figure 4.

[0023] Figure 6 is a graph illustrating correlation between the normalized increases in amplitudes of early systolic components of pulse waves of a segment of an arm as measured in some embodiments and the increases in diameter of the brachial artery measured via ultrasound imaging of the brachial artery.

[0024] Figure 7 is a timing diagram illustrating blood flow and systolic pressure after release of the occlusion in Figure 4.

[0025] Figures 8a and 8b are timing diagrams illustrating, in an expanded view, measured cuff pressure oscillations of a limb during one inflation/deflation cycle of Figure 4 before occlusion and during one cycle of Figure 4, respectively, after occlusion of blood vessels in the limb.

[0026] Figure 9 is a timing diagram illustrating pressure applied to the limb during the baseline testing and analysis and after-stimulus testing and analysis of Figure 3 with an oral administration of nitroglycerin providing a stimulus.

[0027] Figure 10 is a timing diagram illustrating amplitudes of early systolic components of pulse waves measured during a baseline period, a stimulus period, and an after-stimulus period of Figure 9.

[0028] Figure 11 is a flow chart illustrating one embodiment of the operation of arterial volume change assessment of Figure 3.

[0029] Figure 12 is a flow chart illustrating one embodiment of an operation of determining amplitude of the arterial volume change assessments of Figures 3 and 11.

[0030] Figure 13 is a timing diagram illustrating a measured pulse wave for a healthy person.

[0031] Figure 14 is a timing diagram illustrating a measured pulse wave for a patient with cardiovascular disease.

[0032] Figure 15 is a flow chart illustrating one embodiment of an operation of determining changes in arterial volume of the operations of Figures 3 and 11.

[0033] Figures 16A and 16B are flow charts illustrating embodiments of a process for adjusting a reactive hyperemia indicator based on anthropomorphic and/or demographic variables.

DETAILED DESCRIPTION

[0034] A preferred embodiment of the present invention is now described with reference to the figures where like reference numbers indicate identical or functionally similar elements. Also in the figures, the leftmost digits of each reference number corresponds to the figure in which the reference number is first used.

[0035] Figure 1 is a pictorial diagram illustrating a diagnostic system 100 (also referred to herein as the ANGIODEFENDER system) in accordance with the present invention. The diagnostic system 100 comprises a diagnostic device 102, a diagnostic computer 104, a cuff 106, a Doppler transducer 108, and an oxygen saturation (StO₂) sensor 110.

[0036] As used herein, the volume pulse waves are oscillations in the blood pressure between the systolic and the diastolic pressures of arteries. The diagnostic system 100 detects the volume pulse waves and performs diagnostics for assessing arterial volume changes of a limb segment based on the detected pulse waves. In some

embodiments, the volume pulse wave includes a composite pulse wave formed of a superposition of a plurality of component pulse waves. The component pulse waves partially overlap and the arterial pulse wave shape or contour is formed by the superposition of the component pulse waves. The component pulse waves may include, for example, an incident systolic wave (also called early systolic wave), a reflected wave (also called late systolic wave), and other waves. The diagnostic system 100 measures amplitudes of components of arterial volume pulse waves as a way of monitoring the changes in arterial volume of the limb segment after a stimulus. While it may be easier to measure the amplitude of the whole arterial volume pulse wave, the timing of the component pulse waves shifts throughout the testing procedure and changes the shape of the pulse wave. In some embodiments, the diagnostic system 100 measures amplitude of a physiologically significant component (such as a component pulse wave) of the volume pulse wave to assess the changes in arterial volume of the limb segment. The diagnostic system 100 may use any component pulse wave of the detected volume pulse wave or portion thereof (such as maximum, inflection point, or amplitude at a fixed time of the component pulse wave), any portion of the volume pulse wave (such as maximum, inflection point, or amplitude at a fixed time of the volume pulse wave), or a combination thereof for the diagnostics for assessing arterial volume changes. As an illustrative example, the operation of the diagnostic system 100 is described herein in terms of the early systolic wave.

[0037] In use, the cuff 106 is disposed around a limb 120 so that when the cuff 106 is inflated, the cuff 106 constricts a segment of the limb 120. It is understood by those skilled in the art that the measurements of the changes in the arterial volume of

a limb segment described herein are not measuring the volume changes of only a single artery in the limb 120, but are measuring the volume changes in substantially all arteries in the segment of the limb 120 that is being constricted. Although the volume changes measurements and the physiology thereof are described for a single artery, one skilled in the art will recognize that the invention is not restricted to a single artery and that the volume changes measurements are of all or substantially all arteries in the segment of the limb being measured. The limb 120 may be any limb or digits thereof, but for the sake of simplicity, the limb 120 is described as an arm, and the artery that is being evaluated is described as the brachial artery. In some embodiments, the limb 120 is a leg and the artery is a femoral artery. Although the diagnostic system 100 is described for use on a human being, the invention is not so limited. The diagnostic system 100 can be used on other mammals.

[0038] The diagnostic computer 104 provides control signals to the diagnostic device 102 and receives information and detected data from the diagnostic device 102.

[0039] The diagnostic device 102 provides air to and releases air from the cuff 106 via a tube 112 of the cuff 106. The diagnostic device 102 may control, detect and monitor the air pressure in the tube 112. In some embodiments, a gas other than air, or a liquid, such as water, may be used in the cuff 106, the tube 112, and the pneumatic module 202 (see Figure 2). In some embodiments, the cuff can be an electrically-controlled elastomer or a mechanically-controlled material.

[0040] Although the diagnostic system 100 is described herein as applying a pressure via the cuff 106 to the limb 120 to occlude an artery 122 as a stimulus of the

endothelium as blood flows into the artery 122 after release of the occlusion, other forms of stimuli may be provided. In various embodiments, the stimulus of the endothelium comprises a mechanical stimulation, a thermal stimulation, a chemical stimulation, an electrical stimulation, a neurological stimulation, a mental stimulation or a stimulation via physical exercise, or any combination thereof, to induce a change in arterial volume of the limb segment. The stimuli are well known and some of them induce formation of nitric oxide by the endothelial cells lining the walls of the arteries. In some embodiments, the stimulus to the endothelium can also be delivered in any way that transiently and locally increases the blood flow and shear stress at the arterial wall. For instance, this can be achieved by applying ultrasound waves such that it creates turbulence inside a major artery. The chemical stimulation may be, for example, a vasoactive agent, such as an oral administration of nitroglycerol, or an intra-brachial infusion of acetylcholine.

[0041] The diagnostic device 102 provides control signals to and receives measurement signals from the Doppler transducer 108 and the oxygen saturation (StO₂) sensor 110. The Doppler transducer 108 and the oxygen saturation (StO₂) sensor 110 are used in some embodiments for the purpose of quantifying the amount of a vasodilatory stimulus, such as a transient occlusion of the arteries of the limb segment.

[0042] The Doppler transducer 108 is disposed on the limb 120 and adjacent to the artery 122 in the limb 120 and distal or proximal from the cuff 106 for measuring blood flow velocity in the artery 122 using a Doppler process. The Doppler transducer 108 may be any conventional Doppler transducer designed to measure

blood flow velocity in a conduit artery. In some embodiments, the diagnostic system 100 does not include a Doppler transducer 108.

[0043] The oxygen saturation (StO₂) sensor 110 is disposed on the limb 120 and distal from the cuff 106 for measuring oxygen levels in the tissue of the limb to determine the extent to which hemoglobin in the tissue is saturated with oxygen. The oxygen saturation (StO₂) sensor 110 may be any conventional StO₂ sensor. In some embodiments, the diagnostic system 100 does not include an oxygen saturation (StO₂) sensor 110.

[0044] Although the Doppler transducer 108 and the oxygen saturation sensor 110 are described herein as an apparatus to quantify the amount of stimulus via occlusion, other apparatus to quantify the amount of vasoactive stimuli may be provided.

[0045] Although the diagnostic computer 104 is described herein as performing the control, computation, and analysis of the diagnostic system 100, the invention is not so limited. The diagnostic device 102 may include a processor or microcontroller for performing any or all of the operations described herein as being performed by the diagnostic computer 104.

[0046] Although the diagnostic computer 104 is described herein as being local to the blood diagnostic device 102, the diagnostic computer 104 may be coupled to the diagnostic device 102 through a communication line, system, or network, such as the Internet, wireless, or landline. For example, the operation of the diagnostic device 102 may be done near the patient while the diagnostic computer 104 may remotely process the data.

[0047] Figure 2 is a block diagram illustrating the diagnostic device 102. The diagnostic device 102 comprises a pneumatic module 202, a pressure detector 204, a Doppler transducer system 206, an oxygen saturation (StO₂) sensor system 208, and an interface 210. The pneumatic module 202 controls pressure in the cuff 106 in response to control signals from the diagnostic computer 104. The pneumatic module 202 comprises a pump 222 (e.g., an air pump) for pressurizing air, a reservoir 224 for storing the pressurized air, and a pressure controller 226 for controlling the release of air via the tube 112 into the cuff 106.

[0048] The pressure detector 204 comprises a pressure sensor electronics system 228 for controlling a pressure sensor 230, which senses pressure in the cuff 106 via the tube 112. The pressure sensor 230 detects pressure oscillations in the cuff 106 resulting from pulse waves in the artery 122. In some embodiments, the pressure sensor 230 is disposed in the cuff 106 or in the tube 112. In some embodiments, the pressure sensor 230 is a plethysmography sensor, such as a reflective photo-plethysmography sensor.

[0049] The interface 210 communicates control signals and information signals between the diagnostic computer 104 and the pneumatic module 202, the pressure detector 204, the Doppler transducer system 206, and the oxygen saturation (StO₂) sensor system 208. The interface 210 may include a processor or microcontroller for performing any or all of the operations described herein.

[0050] The Doppler transducer system 206 communicates with the Doppler transducer 108 for measuring blood flow velocity in the artery 122. In some embodiments, the diagnostic computer 104 commands the Doppler transducer system

206 to measure blood flow velocity through the artery 122 after the cuff pressure has been released to assess the amount of stimulus delivered via shear stress to the artery 122.

[0051] In some embodiments, the diagnostic computer 104 may include test data of blood velocity and may use such test data to quantify the amount of the post-occlusion stimulus in a patient. The diagnostic computer 104 may use this data as part of the assessment of changes in the arterial volume of the limb segment described herein.

[0052] The oxygen saturation (StO₂) sensor system 208 communicates with the oxygen saturation (StO₂) sensor 110 to measure oxygen levels in the tissue for determining the extent to which the hemoglobin in the blood of the tissue is saturated with oxygen.

[0053] In some embodiments, the diagnostic computer 104 may include test data of oxygen saturation and may use such test data to standardize the degree of limb ischemia among the test subjects, and quantify the amount of the post-occlusion stimulus in a particular patient. The diagnostic computer 104 may use this data as part of the assessment of changes in the arterial volume of the limb segment described herein.

[0054] Figure 3 is a flow chart illustrating an operation of arterial volume change assessment of the diagnostic system 100. Before operating the diagnostic system 100, the cuff 106 is placed around the limb 120 (e.g., arm) of the patient. The test is started with an entry on the diagnostic computer 104 in any well known manner such as keystrokes on a keyboard (not shown) or movement of a cursor and selection of a screen button via a mouse (not shown). In response to an initiation of the diagnostic

command, the diagnostic computer 104 assesses changes in the arterial volume of a segment of the limb 120. The diagnostic computer 104 performs baseline testing and analysis (block 302) during a baseline period 402 (see Figure 4 below). In some embodiments, the diagnostic system 100 detects and analyzes volume pulse waves of a segment of the limb 120 during the baseline period in which no stimulus is applied to the patient. In some embodiments, the analysis of the volume pulse waves includes determining amplitudes of the detected volume pulse waves to calculate a baseline arterial volume of the segment of the limb 120. One embodiment of the baseline testing is described below in conjunction with Figure 4.

[0055] A stimulus is applied to the patient to induce a period of change in arterial volume of the segment of the limb 120 (block 304) during a stimulus period 404 (see Figure 4 below). In some embodiments, the diagnostic computer 104 commands the pneumatic module 202 to pressurize the cuff 106 to a level sufficient to occlude the artery 122. In some embodiments, the cuff 106 is inflated to a pressure above systolic for a period of time sufficient to induce change in arterial volume of the segment of the limb 120 after releasing the cuff pressure.

[0056] The diagnostic computer 104 performs after-stimulus testing and analysis (block 306) during an after-stimulus period 406 (see Figure 4 below). In some embodiments, the diagnostic system 100 detects and analyzes volume pulse waves of a segment of the limb 120 after the stimulus, such as a predetermined time after either starting or terminating the application of the stimulus. In some embodiments, the analysis of the volume pulse waves includes determining amplitudes of early systolic components of the detected volume pulse waves to calculate an after-stimulus arterial volume of the segment of the limb 120. One embodiment of the after-stimulus testing

is described below in conjunction with Figure 4. The analyses of blocks 302 and 306 may be performed separately from the testing and at a later time.

[0057] The diagnostic computer 104 performs an arterial volume change assessment (block 308). In some embodiments, the diagnostic computer 104 calculates the relative change in arterial volume of the limb 120 during the after-stimulus time period 406 (see Figure 4) relative to the arterial volume of the limb 120 during the baseline period 402 (see Figure 4) from the amplitudes of the early systolic component of volume pulse waves at baseline and after the stimulus. One embodiment of the arterial volume change assessment is described below in conjunction with Figure 15.

[0058] In some embodiments, the assessment of the level of hypoxemia (or oxygen saturation) can be included in the arterial volume change assessment (block 308) and achieved by any method that is compatible with the testing procedure (e.g., based on non-pulsatile measurements of hypoxemia if a cuff 106 is used to occlude the artery). In some embodiments, the assessment of post-occlusion blood velocity or blood shear stress can be included in the arterial volume change assessment (block 308) and achieved by any method that is compatible with the testing procedure (e.g., based on Doppler measurements).

[0059] Figure 4 is a timing diagram illustrating pressure applied to the limb 120 during the baseline testing and analysis (block 302) and after-stimulus testing and analysis (block 306) of Figure 3 with an occlusion providing a stimulus. Prior to the procedure described in Figure 4, a patient's blood pressure is measured to select an individualized pressure that will be applied to the limb. During blood pressure

measurements, the diagnostic system 100 determines systolic, diastolic, and mean arterial pressures, which may be done in a conventional manner. Once the blood pressure measurements are performed, the individualized pressure applied to the patient's limb is determined as a percentage of diastolic, or systolic, or mean arterial pressure. It can also be determined according to a formula based on the patient's blood pressure. For instance, the pressure applied to the patient's limb may be computed as the patient's diastolic pressure minus 10 mm Hg. Standardization of the pressure applied to each patient allows the comparison of the test data among patients in whom blood pressures are different.

[0060] As an illustrative example, during a baseline period 402 (e.g., 150 seconds), the diagnostic device 102 measures the resting arterial volume pulse waves of the brachial artery 122, which are indicative of the resting diameter of the brachial artery 122. During the baseline period 402, the diagnostic system 100 commands the diagnostic device 102 to perform a series of rapid inflations 412 and deflations 414 of the cuff 106, and to collect data from the pressure sensor 230. (For the sake of clarity, only ten inflations 412 and ten deflations 414 are shown, but other numbers may be used. For the sake of clarity only one inflation/deflation cycle is labeled.) In each cycle, the cuff is rapidly inflated 412 to a pressure, such as the sub-diastolic arterial pressure, and held inflated 416 for a predetermined time (e.g., 4 to 6 seconds) and then held deflated 418 for a predetermined time (e.g., 4 to 10 seconds). In some embodiments, the diagnostic computer 104 may dynamically determine the time of the inflation 416 and the number of pulses based on the measurements. While the cuff 106 is inflated 416, the diagnostic device 102 detects a plurality of pressure oscillations (or volume pulse waves).

[0061] After the baseline period 402, the diagnostic device 102 inflates the cuff 106 to a supra-systolic pressure (e.g., systolic pressure plus 50 mm Hg) to temporarily occlude the artery 122 for an occlusion period 403 (e.g., about 300 seconds).

Concurrent with the occlusion, the oxygen saturation (StO₂) sensor electronics 208 controls the oxygen saturation (StO₂) sensor 110 to monitor the level of hypoxemia in the limb distal to the occluding cuff.

[0062] Thereafter, the diagnostic device 102 rapidly deflates the cuff 106 (e.g., to a pressure below venous pressure, for instance, below 10 mm Hg) to allow the blood flow to rush into the limb 120 during a stimulus period 404. The pressure release of the cuff 106 creates a rapid increase in the blood flow in the artery 122, which generates shear stress on the endothelium of the brachial artery 122. The shear stress stimulates the endothelial cells to produce nitric oxide (NO), which dilates the artery 122.

[0063] Concurrent with the cuff deflation, the Doppler transducer electronics 206 controls the Doppler transducer 108 to collect data for a predetermined time (e.g., 10-180 seconds) during which time the Doppler transducer 108 measures blood velocity.

[0064] During an after-stimulus period 406, the diagnostic system 100 commands the diagnostic device 102 to perform a series of rapid inflations 422 and deflations 424 of the cuff 106, and to collect data from the pressure sensor 230 in a manner similar to that for the baseline period 402 for a predetermined time (e.g., 1-10 minutes). (For the sake of clarity, only fourteen inflations 422 and fourteen deflations 424 are shown, but other numbers may be used. For the sake of clarity only one inflation/deflation cycle is labeled.) In each series, the cuff is rapidly inflated to a

pressure, and held inflated 426 for a predetermined time (e.g., 4 to 6 seconds), and then deflated 428. In some embodiments, the diagnostic computer 104 may dynamically determine the time of the inflation 426 and the number of pulses detected based on the measurements. During this time, the diagnostic computer 104 monitors the dynamics of changes in arterial volume of a limb segment (a gradual increase in pulse wave amplitude to maximum and then a gradual decrease in the pulse wave amplitude to return to a resting state).

[0065] Figure 5 is a timing diagram illustrating amplitudes of early systolic components of pulse waves measured during the baseline period 402 and the after-stimulus period 406 of Figure 4.

[0066] Figure 6 is a graph illustrating correlation between the normalized increases in amplitudes of early systolic components of volume pulse waves of a segment of an arm as measured in some embodiments and the increases in diameter of a brachial artery measured via ultrasound imaging of the brachial artery. Each data point in the graph corresponds to a different patient. The stimulus in both methods was a 5-minute occlusion of the brachial artery via cuff inflation to a supra-systolic pressure. A normalization of the test results obtained with the present invention accounts for the fact the diagnostic system 100 assesses the change in the volume of substantially all arteries in the limb segment, while the ultrasound imagining visualizes only the main artery.

[0067] Figure 7 is a timing diagram illustrating blood flow and systolic pressure after release of the occlusion in Figure 4 during the stimulus period 404. A line 701 shows

a rapid increase in blood flow followed by a decrease to normal flow. A line 702 shows the temporary drop in systolic pressure after the occlusion.

[0068] Figures 8a and 8b are timing diagrams illustrating measured cuff pressure oscillations of the limb 120 during one inflation/deflation cycle before occlusion (Fig. 8a) and during one cycle after occlusion (Fig. 8b) of blood vessels in the limb 120 in an expanded view. During the cuff pressure sequence, data is collected about the oscillations in the cuff pressure due to the pulsation of the brachial artery. The changes in the oscillatory amplitude (or the amplitude of a pulse wave) are related to the changes in the radius of the brachial artery, and Figure 8b shows the pulse wave amplitude after occlusion being larger than the pulse wave amplitude before occlusion.

[0069] In some embodiments, arterial volume pulse waves are detected using an external pressure that is applied to the segment of the limb 120. In some embodiments, the externally applied pressure varies gradually between near-systolic and near-diastolic. In some embodiments, the external pressure is applied by initially applying the external pressure at a pressure near systolic, and gradually reducing the external pressure to a pressure near diastolic. In some embodiments, the external pressure is applied by initially applying the external pressure at a pressure near diastolic, gradually increasing to a pressure near systolic at a rate to allow the oscillations to be detected, and then quickly decreasing the pressure.

[0070] In some embodiments, as shown in Figures 4 and 9, an applied external pressure is cycled between a high level and a low level so that the arterial volume pulse waves are determined while the external pressure is at the high level. In some

embodiments, the high level is below diastolic pressure and the low level is below venous pressure.

[0071] In some embodiments, the high level 416 or 426 is maintained for no more than 10 seconds in any cycle. In some embodiments, the low level 418 or 428 is maintained for at least 4 seconds in any cycle. In some embodiments, the measurements are taken over at least one cardiac cycle.

[0072] Figure 9 is a timing diagram illustrating pressure applied to the limb 120 during the baseline testing and analysis (block 302) and after-stimulus testing and analysis (block 306) of Figure 3 with an oral administration of nitroglycerin providing a stimulus. Because there is no occlusion period 403, the diagnostic system 100 generates a series of rapid inflations 422 and deflations 424 with an inflation state 426 and measures the volume pulse waves during the baseline period 402, the stimulus period 404 and the after-stimulus period 406.

[0073] Figure 10 is a timing diagram illustrating amplitudes of early systolic components of pulse waves measured during the baseline period 402, the stimulus period 404 and the after-stimulus period 406 of Figure 9.

[0074] Figure 11 is a flow chart illustrating one embodiment of the operation of arterial volume change assessment (block 308 of Figure 3). In response to an initiation of the diagnostic command from the user, the diagnostic computer 104 assesses change in the arterial volume of a segment of the limb 120. The diagnostic device 102 detects volume pulse waves of a segment of the limb during the baseline period 402, such as described above in conjunction with Figures 4-8 (or Figures 9-10, depending on the stimulus) (block 1102). In some embodiments, the diagnostic

computer 104 commands the pneumatic module 202 to pressurize the cuff 106 to a level sufficient for the pressure detector 204 to detect volume pulse waves of a segment of the limb 120.

[0075] The diagnostic device 102 determines amplitudes of early systolic components of the detected volume pulse waves (block 1104). In some embodiments, the diagnostic computer 104 commands the pressure detector 204 to detect volume pulse waves of the segment of the limb 120. The diagnostic computer 104 analyzes the waveforms of the detected volume pulse waves and determines relevant amplitudes of the volume pulse waves for the baseline period. In one embodiment, the relevant amplitude of a pulse wave is the difference between the maximum and the minimum pressures of the pulse wave. In some embodiments, the relevant amplitude is the amplitude of the early systolic component. One embodiment for determining amplitudes of block 1104 is described below in conjunction with Figure 12. (Blocks 1102 and 1104 may be used for the block 302 of Figure 3).

[0076] The diagnostic device 102 applies a stimulus during the stimulus period 402 to induce a period of change in arterial volume of the segment of the limb 120 (block 1106). In some embodiments, the diagnostic computer 104 commands the pneumatic module 202 to pressurize the cuff 106 to a level sufficient for occluding the artery 122. (Block 1106 may be used for the block 306 of Figure 3; other examples of stimuli are described above in conjunction with Figure 1 and Figures 9-10).

[0077] The diagnostic device 102 detects volume pulse waves of the segment of the limb 120 during the after-stimulus period 406 to detect change in arterial volume of a limb segment, such as described above in conjunction with Figures 4-8 (block 1108).

In some embodiments, the diagnostic computer 104 commands the pneumatic module 202 to pressurize the cuff 106 to a level sufficient for the pressure detector 204 to detect volume pulse waves of a segment of the limb 120.

[0078] The diagnostic device 102 determines amplitudes of early systolic components of the detected volume pulse waves after the stimulus (block 1110). In some embodiments, the diagnostic computer 104 commands the pressure detector 204 to detect volume pulse waves of the segment of the limb 120. The diagnostic computer 104 analyzes the waveforms of the detected volume pulse waves and determines relevant amplitudes of the volume pulse waves for the baseline period. In one embodiment, the relevant amplitude of a pulse wave is the difference between the maximum and the minimum pressures of the pulse wave. In some embodiments, the relevant amplitude is the amplitude of the early systolic component. One embodiment for determining amplitudes of block 1110 is described below in conjunction with Figure 12. (Blocks 1108 and 1110 may be used for the block 306 of Figure 3).

[0079] The diagnostic device 102 performs an arterial volume change assessment (block 1112). In some embodiments, the diagnostic computer 104 calculates the relative change in arterial volume of the limb segment 120 during the after-stimulus time period 406 relative to the arterial volume of the limb 120 during the baseline period 402 from the amplitudes of the early systolic component of volume pulse waves at baseline and after the stimulus. In some embodiments, the diagnostic computer 104 calculates the relative change by comparing the amplitudes of early systolic component of volume pulse waves at baseline (block 1104) and after the stimulus (block 1106). (Block 1112 may be used for the block 308 of Figure 3). One

embodiment of the arterial volume change assessment is described below in conjunction with Figure 15.

[0080] Figure 12 is a flow chart illustrating one embodiment of an operation of determining amplitude of the arterial volume change assessments (block 308 of Figure 3 and block 1112 of Figure 11). The diagnostic computer 104 determines the amplitude of the early systolic component of a volume pulse wave by computing fourth derivative of the detected volume pulse wave (block 1202). The diagnostic computer 104 determines a time at which the fourth derivative crosses the zero-line for the third time (block 1204). (A third zero-line crossing 1322 of Figure 13 below and a third zero-line crossing 1422 of Figure 14 below.) In some embodiments, the diagnostic computer 104 may instead determine the second derivative of the detected volume pulse wave. In some embodiments, the diagnostic computer 104 may instead determine an inflection point in the volume pulse wave and use the time of occurrence of the inflection point. In some embodiments, the diagnostic computer 104 may instead use Fourier transformation of the volume pulse wave to determine the time of occurrence of the peaks of the pulse component pulse waves.

[0081] The diagnostic computer 104 determines a pressure value on the detected volume pulse wave at that time (block 1206). The diagnostic computer 104 determines a pressure value at the beginning of the volume pulse wave (block 1208). In some embodiments, the diagnostic computer 104 determines the pressure value at the beginning of the volume pulse wave by determining a minimum during the diastolic component of the pulse wave. The diagnostic computer 104 assesses the amplitude of the early systolic component of the volume pulse wave as the difference between the pressure values (block 1210).

[0082] In some embodiments, the diagnostic computer 104 may compute other orders of derivatives in block 1202, or not compute a derivative, but instead determine the inflection point corresponding to the peak of the early systolic component of the pulse wave by other methods. In other embodiments, the diagnostic computer 104 may determine the maximum amplitude of the arterial volume pulse waves.

[0083] Figure 13 is a timing diagram illustrating a measured pulse wave for a healthy person. A pulse wave 1300 includes an early systolic component 1302 and a late systolic component 1304. (The pulse wave 1300 may include other component pulse waves, which are not shown.) The early systolic component 1302 forms an inflection point 1310 in the pulse wave 1300. Because of the amplitude and the timing of the late systolic component 1304, the maximum of the pulse wave 1300 coincides with the peak of the early systolic component 1310. A line 1320 is a fourth derivative of the pulse wave 1300 and includes a third zero-line crossing point 1322. The crossing point 1322 is used to determine the time and amplitude 1312 of the early systolic component.

[0084] During the after-stimulus period, the shape of the arterial volume pulse wave changes to a pulse wave 1350. The pulse wave 1350 includes an early systolic component 1352 and a late systolic component 1354. (The pulse wave 1350 may include other component pulse waves, which are not shown.) The early systolic component 1352 forms an inflection point 1360 in the pulse wave 1350. During the after stimulus period, the amplitude and the timing of the late systolic component 1352 change slightly and the maximum 1366 of the pulse wave 1350 no longer coincides with the peak of the early systolic component 1360. Yet, the amplitude

1362 of the early systolic component 1352 and the amplitude (distance 1362 plus the distance 1364) of the maximum 1366 of the pulse wave 1350 differ slightly.

[0085] Figure 14 is a timing diagram illustrating a measured pulse wave for a patient with cardiovascular disease. A pulse wave 1400 includes an early systolic component 1402 and a late systolic component 1404. (The pulse wave 1400 may include other component pulse waves, which are not shown.) The early systolic component 1402 forms an inflection point 1410 in the pulse wave 1400. Because of the amplitude and the timing of the late systolic component 1404, the maximum of the pulse wave 1400 coincides with the peak of the early systolic component 1410. A line 1420 is a fourth derivative of the pulse wave 1400 and includes a third zero-line crossing point 1422. The crossing point 1422 is used to determine the time and amplitude 1412 of the early systolic component.

[0086] During the after-stimulus period, the shape of the arterial volume pulse wave changes to a pulse wave 1450. A pulse wave 1450 includes an early systolic component 1452 and a late systolic component 1454. (The pulse wave 1450 may include other component pulse waves, which are not shown.) The early systolic component 1452 forms an inflection point 1460 in the pulse wave 1450. During the after stimulus period the amplitude and the timing of the late systolic component change significantly and the maximum 1466 of the pulse wave 1450 no longer coincides with the peak of the early systolic component 1460. The amplitude 1462 of the early systolic component 1452 and the amplitude (distance 1462 plus the distance 1464) of the maximum 1466 of the pulse wave 1450 differ significantly.

[0087] The diagnostic system 100 may use the differences in the pulse wave characteristics of Figures 13-14 to compute arterial indexes (for instance, the augmentation index) to assess the cardiovascular status of the patient.

[0088] Figure 15 is a flow chart illustrating one embodiment of an operation of determining changes in arterial volume of the operations of Figures 3 and 11. The diagnostic computer 104 determines average pulse wave amplitude per each inflation/deflation cycle over the measurement period and obtains a graph such as the graph described above in conjunction with Figure 5.

[0089] The diagnostic computer 104 calculates an average ($AVG_{baseline}$) of the calculated average amplitudes of the early systolic components of pulse wave measured during the baseline 402 (block 1502). For the after-stimulus period 406, the diagnostic computer 104 calculates a curve that fits the after-stimulus data of the early systolic components of pulse wave measured during the after-stimulus 406 (block 1504), using for example, a fourth-order polynomial function. The diagnostic computer 104 calculates a maximum (MAX_{after}) of the fitted curve of the after-stimulus data (block 1506). The diagnostic computer 104 calculates a time from the end of the occlusion (or other stimulus) to the maximum of the fitted curve of the after-stimulus data (block 1508). The diagnostic computer 104 calculates a relative amplitude change from the baseline to the maximum of the fitted curve of the after-stimulus data (block 1510).

[0090] The diagnostic computer 104 calculates relative change in arterial volume ΔV (block 1512) as follows:

$$\Delta V = [(MAX_{after} - AVG_{baseline}) / AVG_{baseline}]$$

[0091] The diagnostic computer 104 calculates relative change in arterial radius as follows (block 1512):

$$\Delta R = [(\Delta V + 1)^{1/2} - 1],$$

The relative change in radius ΔR is defined as follows:

$$\Delta R = [(R_{\text{after}} - R_{\text{baseline}})/R_{\text{baseline}}],$$

where R_{after} is the maximum after-stimulus radius of the artery and R_{baseline} is the arterial radius at baseline.

[0092] In some embodiments, the diagnostic computer 104 may compute an area under the fitted curve for the after-stimulus data, in addition to or instead of the determination of the maximum of the fitted curve of block 1506. In some embodiments, the diagnostic computer 104 determines the area under the curve by integrating the fitted polynomial function of block 1504 from the time the stimulus ends to either the time when the measured amplitude returns to the baseline or to the end of the test. In some embodiments, the diagnostic computer 104 extrapolates the fitted curve of block 1504 to the time at which the measured amplitude returns to baseline. In some embodiments, the diagnostic computer 104 computes other parameters (e.g., the width at half-height) from the fitted curve of block 1504 to calculate the relative change in arterial volume.

[0093] The diagnostic computer 104 may provide any or all of the raw data and processed data to a doctor or clinical researcher via a display, paper or other manners well known to those skilled in the art. In some embodiments, the diagnostic computer 104 provides a doctor processed data such as 1) relative % change in arterial volume of a limb segment after a stimulus (for example, after 5 min cuff occlusion, the arterial volume changed by 57%) as a reflection of the ability of the arteries to dilate

in response to the stimulus; 2) computed relative maximum %change in the radius of the artery after the stimulus; time to maximum change in arterial volume (for instance, 72 sec); 4) area under the curve; and 5) pulse wave characteristics (time difference between the peaks of early and late systolic waves, augmentation index, etc.) as indicators of arterial stiffness. In some embodiments, the diagnostic computer 104 provides a doctor raw data, such as detected volume pulse waves in each inflation/deflation cycles.

[0094] Although the diagnostic system 100 is described as including one cuff 106, other numbers of cuffs 106 may be used. In some embodiments, the diagnostic system 100 includes two cuffs 106. One cuff 106 is disposed on the limb 120 and occludes the artery 122, and the other cuff 106 is disposed on the limb 120 distal to the first cuff 106, and detects the pressure oscillations. Alternatively, one cuff 106 is disposed on the limb 120 and detects the pressure in the artery 122, and the other cuff 106 is disposed on the limb 120 distal to the first cuff 106, and occludes the artery 122.

[0095] In an embodiment, the diagnostic computer 104 can provide a percentage of flow-mediated dilation (%FMD), that has been used as an indicator of endothelial function. The %FMD can be determined by the diagnostic computer 104 based on the change in arterial volume post-occlusion vs. pre-occlusion, which, in turn, can be determined from the percent change in blood pressure post-occlusion vs. pre-occlusion, as measured by cuff 106 and reflected as pulse wave amplitude changes by pressure sensor 230 (described above with respect to Figs. 1 and 2). This unadjusted %FMD determined by diagnostic computer 104 will henceforth be referred to as “AD-%FMD_U” to indicate that it is derived from the ANGIODEFENDER system

described above and in the '400 patent. While AD-%FMD_U is comparable to %FMD determined using brachial artery ultrasound imaging (BAUI-%FMD), the gold standard for measuring flow-mediated dilation, the correlation between AD-%FMD_U and BAUI-%FMD¹ can be further optimized. Therefore, the present inventors have developed an algorithm, based on anthropomorphic and/or demographic factors, for adjusting AD-%FMD_U to better correlate with BAUI-%FMD.

[0096] Based on data obtained using the ANGIODEFENDER system in a 29-person clinical pilot study conducted at Yale University in June through August of 2014, the present inventors initially determined that segregation of subjects by lean body mass (LBM), followed by subsequent adjustments to the subjects' AD-%FMD_U based on mean arterial pressure (MAP) and pulse pressure (PP) or systolic blood pressure divided by diastolic blood pressure (SBP/DBP), yielded "adjusted AD-%FMD" (hereinafter AD-%FMD_A) values that were more comparable (based on Deming regression analysis) to BAUI-%FMD. It was further determined that both steps performed in the given order – LBM segregation first followed by subsequent adjustment of MAP, PP, or SBP/DBP – were necessary to achieve AD-%FMD_A values that correlate well with BAUI-%FMD and, therefore, provide an improved endothelial function indicator.

[0097] Figs. 16A and 16B illustrates the initial adjustment processes 1600A and 1600B the inventors applied to AD-%FMD_U values to obtain AD-%FMD_A values that more closely approximate BAUI-%FMD. At blocks 1602A (in Fig. 16A) and 1602B

¹ It should be noted that BAUI-%FMD, as used herein, includes both unadjusted BAUI-%FMD measurements and BAUI-%FMD measurements that have been adjusted based on baseline brachial artery size or other allometric factors. Unadjusted BAUI-%FMD is calculated based on the percent change in brachial artery diameter post-occlusion vs. pre-occlusion.

(in Fig. 16B), AD-%FMD_U values were determined using the ANGIODEFENDER technology. Specifically, at block 1602A, AD-%FMD_U values were determined according to the following equation:

$$\text{AD-FMD}_U = \left[\left[\frac{\text{PWA}_{\text{MAX}} - \text{PWA}_{\text{PREOCC}}}{\text{PWA}_{\text{PREOCC}}} + 1 \right]^{1/2} - 1 \right] * [100/C]$$

PWA_{MAX}: Maximum post-occlusion pulse wave amplitude (PWA)
PWA_{PREOCC}: Median pre-occlusion PWA
C = 3.4

At block 1602B, AD-%FMD_U values were determined according to the following equation:

$$\text{AD-FMD}_U = \{[(\text{FMD}_1 + 1)^{0.5}] - 1\} * 100/C, \text{ where } \text{FMD}_1 = \{[\text{PWA}_{\text{max}}/(\text{PWA}_{\text{preocc}})^d] - 1\} / \text{PWA}_{\text{preocc}}$$

C=3.4

d=1

PWA_{max} = Maximum post-occlusion pulse wave amplitude (PWA)

PWA_{preocc} = Median pre-occlusion PWA

[0098] At step 1604, the AD-%FMD_U values were segregated based on LBM. LBM was determined according to the following equation:

$$\text{LBM (Lean Body Mass; kg)} = ((100 - \%BF)/100) * \text{BMI} * \text{BSA}$$

$$\%BF (\% \text{ body fat}) = (((\text{Wt}/((\text{Ht}/100)^2)) * 1.2) + (\text{Age} * 0.23) - (\text{Gender} * 10.8) - 5.4)$$

Wt = weight (kg)
Ht = height (cm)
Age = years
Gender = male (1); female (0)

$$\text{BMI (Body Mass Index)} = \text{Wt}/((\text{Ht}/100)^2)$$

$$\text{BSA (Body Surface Area)} = 0.007184 * (\text{Ht}^{0.725}) * (\text{Wt}^{0.425})$$

It should be noted, however, that alternate equations or methods can be used to calculate LBM, as well as BMI and BSA. It is believed that segregation based on LBM is important as a first adjustment step because the cardiovascular system has evolved for efficient distribution of metabolic substrates, such as oxygen, to tissue mass with high metabolic potential (e.g. LBM). LBM may be more reflective of metabolic potential than other body size variables, such as weight. It should also be noted that in some embodiments anthropomorphic and/or demographic factors other than LBM can be used to segregate the AD-%FMD_U values. Examples of such factors include height, weight, age, gender, BMI, or BSA.

[0099] In the initial adjustment processes 1600A and 1600B, 35 kilograms (kg) was used as the threshold value by which to segregate LBM measurements. Thus, at block 1606A, subjects with LBM of 35 kg or greater were separated, and at block 1606B, subjects with LBM of less than 35 kg were separated.

[00100] At block 1608A, the AD-%FMD_U of subjects with LBM greater than or equal to 35kg was divided by MAP² to arrive at the AD-%FMD_A. At block 1608B (in Fig. 16A), the AD-%FMD_U of subjects with LBM less than 35kg was divided by PP² to arrive at the AD-%FMD_A. Alternatively, at block 1608C (in Fig. 16B), the AD-%FMD_U of subjects with LBM less than 35kg was divided by (SBP/DBP)² to arrive at the AD-%FMD_A. MAP, PP, SBP, and DBP can all be determined by the diagnostic system 100 during baseline testing, prior to occlusion.

[00101] In an embodiment, the steps and equations of process 1600A can all be combined into a single equation in which LBM segregation is taken into account. In one embodiment, the equation is as follows:

$$\text{AD-}\% \text{FMD}_A = [\text{Int} + \{(10^7 * \text{AD-}\% \text{FMD}_U) / (\text{Xpp} * ([j * \text{PP}]^z) + (1 - \text{Xmap}) * ([k * \text{MAP}]^w))\}] / \text{slope}$$

where:

Int = y-intercept of a least-squares regression line of $\{(10^7 * \text{AD-}\% \text{FMD}_U) / (\text{Xpp} * ([j * \text{PP}]^z) + (1 - \text{Xmap}) * ([k * \text{MAP}]^w))\}$ vs BAUI-%FMD

$$\text{Xpp} = ae^{[-be^{(-c * (D_{PP} - \text{LBM}))}]}$$

$$\text{Xmap} = ae^{[-be^{(-c * (D_{MAP} - \text{LBM}))}]}$$

slope = slope of a least-squares regression line of $\{(10^7 * \text{AD-}\% \text{FMD}_U) / (\text{Xpp} * ([j * \text{PP}]^z) + (1 - \text{Xmap}) * ([k * \text{MAP}]^w))\}$ vs BAUI-%FMD

Constants: **j, z, k, w, a, b, c, Dpp, Dmap**

$[\text{constant}]^{\text{value}}$ = ‘constant’ raised to the power designated by the ‘value’, in base 10

$[\text{constant}]e^{\text{value}}$ = ‘constant’ raised to the power designated by the ‘value’, in base e

In an example, the constant j is equal to about 4.4, the constant k is equal to about 0.5, the constant z is equal to about 3.2, the constant w is equal to about 4.5, the constant a is equal to about 1, the constant b is equal to about 2, and the constant c is equal to about 0.8. In an example, Dpp is equal to about 31.9, Dmap is equal to about 33.4, slope is equal to about 0.7 and Int is equal to about 2.6.

[00102] Likewise, in another embodiment, the steps and equations of process 1600B can all be combined into a single equation in which LBM segregation is taken into account:

$$\text{AD-}\% \text{FMD}_A = [\text{Int} + \{(10^7 * \text{AD-}\% \text{FMD}_U) / (\text{X}_{(\text{SBP}/\text{DBP})} * ([j * (\text{SBP}/\text{DBP})]^z) + (1 - \text{Xmap}) * ([k * \text{MAP}]^w))\}] / \text{slope}$$

where:

Int = y-intercept of a least-squares regression line of $\{(10^7 * AD\text{-}\%FMD_U) / (X_{(SBP/DBP)} * ([j * (SBP/DBP)]^z) + (1 - X_{map}) * ([k * MAP]^w))\}$ vs BAUI-%FMD

$X_{(SBP/DBP)} = ae^{[-be^{(-c * (D_{(SBP/DBP)} - LBM))}]}$

$X_{map} = ae^{[-be^{(-c * (D_{MAP} - LBM))}]}$

slope = slope of a least-squares regression line of $\{(10^7 * AD\text{-}\%FMD_U) / (X_{(SBP/DBP)} * ([j * (SBP/DBP)]^z) + (1 - X_{map}) * ([k * MAP]^w))\}$ vs BAUI-%FMD

Constants: **j, z, k, w, a, b, c, D_(SBP/DBP), D_{map}**

[constant]^[value] = ‘constant’ raised to the power designated by the ‘value’, in base 10

[constant]e^[value] = ‘constant’ raised to the power designated by the ‘value’, in base e

In an example, the constant **j** is equal to about 62.1, the constant **k** is equal to about 0.5, the constant **z** is equal to about 4, the constant **w** is equal to about 5, the constant **a** is equal to about 1, the constant **b** is equal to about 2.8, and the constant **c** is equal to about 2.4. In an example, **D_{pp}** is equal to about 36, **D_{map}** is equal to about 34.5, **slope** is equal to about 0.725 and **Int** is equal to about -1.75.

[00103] In the above equations, MAP and PP or (SBP/DBP) are weighted differentially based on LBM. The greater the LBM, the more heavily MAP is weighted in the equation. Conversely, the smaller the LBM, the more heavily the PP or (SBP/DBP) are weighted in the equation.

[00104] In an embodiment, AD-%FMD_A can be calculated by a processor (not shown) located within diagnostic computer 104. In an alternative embodiment, raw data (e.g., LBM, MAP, PP, SBP, DBP, AD-%FMD_U, and BAUI-%FMD) from the diagnostic computer 104 can be communicated, via wired or wireless means, to an external processor (not shown) configured to calculate AD-%FMD_A. The diagnostic

computer 104 can further be configured to communicate the $AD\text{-}\%FMD_A$ to a clinician (e.g., a doctor, a nurse, a healthcare worker, or a clinical researcher).

[00105] While the above equation for $AD\text{-}\%FMD_A$ requires $AD\text{-}\%FMD_U$ as an input value, other measures of reactive hyperemia can be used in place of $AD\text{-}\%FMD_U$. For example, other hemodynamic parameters can be used to measure reactive hyperemia after a stimulus has been applied to a subject. Some examples of such hemodynamic parameters include a blood volume; a blood pressure; an amplitude, frequency, or shape of a plethysmographic wave; a blood vessel diameter; peripheral arterial tone changes; or any derivative thereof. These hemodynamic parameters that serve as indicators of reactive hyperemia can be adjusted, similar to $AD\text{-}\%FMD_U$.

[00106] In addition, temperature can be used as a measure of reactive hyperemia. A change in the temperature of a digit (e.g., a fingertip) post-stimulus vs. pre-stimulus is an indication of reactive hyperemia and can therefore be adjusted according the above equation, similar to $AD\text{-}\%FMD_U$. A change in fingertip temperature can be detected by a temperature sensor (not shown) communicatively linked to the diagnostic device 102 and/or the diagnostic computer 104.

[00107] Reference in the specification to “some embodiments” means that a particular feature, structure, or characteristic described in connection with the embodiments is included in at least one embodiment of the invention. The appearances of the phrase “in some embodiments” in various places in the specification are not necessarily all referring to the same embodiment.

[00108] Some portions of the detailed description that follows are presented in terms of algorithms and symbolic representations of operations on data bits within a

computer memory. These algorithmic descriptions and representations are the means used by those skilled in the data processing arts to most effectively convey the substance of their work to others skilled in the art. An algorithm is here, and generally, conceived to be a self-consistent sequence of steps (instructions) leading to a desired result. The steps are those requiring physical manipulations of physical quantities. Usually, though not necessarily, these quantities take the form of electrical, magnetic or optical signals capable of being stored, transferred, combined, compared and otherwise manipulated. It is convenient at times, principally for reasons of common usage, to refer to these signals as bits, values, elements, symbols, characters, terms, numbers, or the like. Furthermore, it is also convenient at times, to refer to certain arrangements of steps requiring physical manipulations of physical quantities as modules or code devices, without loss of generality.

[00109] However, all of these and similar terms are to be associated with the appropriate physical quantities and are merely convenient labels applied to these quantities. Unless specifically stated otherwise as apparent from the following discussion, it is appreciated that throughout the description, discussions utilizing terms such as “processing” or “computing” or “calculating” or “determining” or “displaying” or “determining” or the like, refer to the action and processes of a computer system, or similar electronic computing device, that manipulates and transforms data represented as physical (electronic) quantities within the computer system memories or registers or other such information storage, transmission or display devices.

[00110] Certain aspects of the present invention include process steps and instructions described herein in the form of an algorithm. It should be noted that the process steps

and instructions of the present invention could be embodied in software, firmware or hardware, and when embodied in software, could be downloaded to reside on and be operated from different platforms used by a variety of operating systems.

[00111] The present invention also relates to an apparatus for performing the operations herein. This apparatus may be specially constructed for the required purposes, or it may comprise a general-purpose computer selectively activated or reconfigured by a computer program stored in the computer. Such a computer program may be stored in a computer readable storage medium, such as, but is not limited to, any type of disk including floppy disks, optical disks, CD-ROMs, magnetic-optical disks, read-only memories (ROMs), random access memories (RAMs), EPROMs, EEPROMs, magnetic or optical cards, application specific integrated circuits (ASICs), or any type of media suitable for storing electronic instructions, and each coupled to a computer system bus. Furthermore, the computers referred to in the specification may include a single processor or may be architectures employing multiple processor designs for increased computing capability.

[00112] The algorithms and displays presented herein are not inherently related to any particular computer or other apparatus. Various general-purpose systems may also be used with programs in accordance with the teachings herein, or it may prove convenient to construct more specialized apparatus to perform the required method steps. The required structure for a variety of these systems will appear from the description below. In addition, the present invention is not described with reference to any particular programming language. It will be appreciated that a variety of programming languages may be used to implement the teachings of the present

invention as described herein, and any references below to specific languages are provided for disclosure of enablement and best mode of the present invention.

[00113] Any numerical values or ranges presented herein include a range of +100% to -50% when proceeded by terms like “about” or “approximately.”

[00114] While particular embodiments and applications of the present invention have been illustrated and described herein, it is to be understood that the invention is not limited to the precise construction and components disclosed herein and that various modifications, changes, and variations may be made in the arrangement, operation, and details of the methods and apparatuses of the present invention without departing from the spirit and scope of the invention as it is defined in the appended claims.

CLAIMS

What is claimed is:

1. A method for assessing endothelial function in a mammal, the method comprising:
 - applying a stimulus to generate reactive hyperemia;
 - measuring a reactive hyperemia indicator;
 - adjusting the reactive hyperemia indicator based on an anthropomorphic and/or demographic variable to arrive at an endothelial function indicator; and
 - communicating the endothelial function indicator to a clinician.
2. The method of claim 1, wherein the anthropomorphic or demographic variable comprises a lean body mass of the mammal.
3. The method of claim 1, wherein the reactive hyperemia indicator comprises at least one of a hemodynamic parameter or a temperature.
4. The method of claim 3, wherein the hemodynamic parameter comprises at least one of a volume; a pressure; an amplitude, a frequency, or a shape of a plethysmographic wave form; a blood vessel diameter; peripheral arterial tone changes; or any derivative thereof.
5. The method of claim 3, wherein the temperature comprises a fingertip temperature.
6. The method of claim 1, wherein the reactive hyperemia indicator comprises a percentage of flow-mediated dilation.
7. The method of claim 6, wherein measuring the percentage of flow-mediated dilation comprises assessing a change in arterial volume of a limb segment of the mammal.

8. The method of claim 7, wherein assessing the change in arterial volume of the limb segment comprises:
 - determining amplitudes of component pulse waves of detected volume pulse waves of the limb segment detected during a baseline period prior to applying the stimulus to determine a baseline arterial volume;
 - determining amplitudes of component pulse waves of detected volume pulse waves of the limb segment detected during a time period after the stimulus has been applied to determine a post-stimulus arterial volume; and
 - determining relative change in arterial volume of the limb segment based on the difference between the baseline arterial volume and the post-stimulus arterial volume.
9. The method of claim 8, wherein the component pulse wave is an early systolic component.
10. The method of claim 6, wherein adjusting the reactive hyperemia indicator comprises approximating a measure of reactive hyperemia based on brachial artery ultrasound imaging.
11. The method of claim 1, wherein the adjusting step further comprises using an algorithm to adjust the reactive hyperemia indicator based upon (i) a lean body mass of the mammal and (ii) at least one of a pulse pressure, a systolic blood pressure, a diastolic blood pressure, and a mean arterial pressure of the mammal.
12. The method of claim 11, wherein the pulse pressure, the systolic blood pressure, the diastolic blood pressure, and the mean arterial pressure are determined prior to measuring the reactive hyperemia indicator.
13. The method of claim 11, wherein the adjusting step further comprises using the algorithm to adjust the reactive hyperemia indicator based upon the pulse pressure and the mean arterial pressure, and wherein the pulse pressure and the mean arterial pressure are differentially weighted in the algorithm.

14. The method of claim 13, wherein the greater the lean body mass, the more the mean arterial pressure is weighted in the algorithm.

15. The method of claim 13, wherein the smaller the lean body mass, the more the pulse pressure is weighted in the algorithm.

16. The method of claim 13, wherein the algorithm comprises:

$$\text{AD-FMD}_U = \left[\left[\frac{\text{PWA}_{\text{MAX}} - \text{PWA}_{\text{PREOCC}}}{\text{PWA}_{\text{PREOCC}}} + 1 \right]^{1/2} - 1 \right] * [100/C]$$

PWA_{MAX}: Maximum post-occlusion pulse wave amplitude (PWA)
PWA_{PREOCC}: Median pre-occlusion PWA
C = 3.4

wherein AD-FMD_U comprises an unadjusted percentage of flow-mediated dilation as determined by ANGIODEFENDER technology.

17. The method of claim 11, wherein the adjusting step further comprises using the algorithm to adjust the reactive hyperemia indicator based upon the ratio of systolic blood pressure to diastolic blood pressure and the mean arterial pressure, and wherein the ratio of systolic blood pressure to diastolic blood pressure and the mean arterial pressure are differentially weighted in the algorithm.

18. The method of claim 17, wherein the greater the lean body mass, the more the mean arterial pressure is weighted in the algorithm.

19. The method of claim 17, wherein the smaller the lean body mass, the more the ratio of systolic blood pressure to diastolic blood pressure is weighted in the algorithm.

20. The method of claim 17, wherein the algorithm comprises:

$$\text{AD-FMD}_U = \{[(\text{FMD}_1 + 1)^{0.5}] - 1\} * 100/C;$$

wherein $FMD_1 = \{[PWA_{\max}/(PWA_{\text{preocc}})^d]-1\}/PWA_{\text{preocc}}$, $C=3.4$, $d=1$, $PWA_{\max}$ = Maximum post-occlusion pulse wave amplitude (PWA), PWA_{preocc} = Median pre-occlusion PWA, and AD-FMD_U comprises an unadjusted percentage of flow-mediated dilation as determined by ANGIODEFENDER technology.

21. The method of claim 1, wherein the applied stimulus comprises at least one of a mechanical stimulation, a thermal stimulation, a chemical stimulation, an electrical stimulation, a neurological stimulation, a mental stimulation, or a physical exercise stimulation.

22. The method of claim 1, wherein the applied stimulus comprises an inflated cuff disposed on a limb segment of the mammal, the inflated cuff imparting a supra-systolic pressure for a time period sufficient to induce reactive hyperemia upon release of the supra-systolic pressure.

23. A system for assessing endothelial function in a mammal, the system comprising:

- a means for applying a stimulus to generate reactive hyperemia;
- a means for measuring a reactive hyperemia indicator;
- a means for adjusting the reactive hyperemia indicator based on an anthropomorphic or demographic variable to arrive at an endothelial function indicator; and
- a means for communicating the endothelial function indicator to a clinician.

24. The system of claim 23, wherein the anthropomorphic or demographic variable comprises a lean body mass of the mammal.

25. The system of claim 23, wherein the reactive hyperemia indicator comprises at least one of a hemodynamic parameter or a temperature.

26. The system of claim 25, wherein the hemodynamic parameter comprises at least one of a volume; a pressure; an amplitude, a frequency, or a shape

of a plethysmographic wave form; a blood vessel diameter; peripheral arterial tone changes; or any derivative thereof.

27. The system of claim 25, wherein the temperature comprises a fingertip temperature.

28. The system of claim 23, wherein the reactive hyperemia indicator comprises a percentage of flow-mediated dilation.

29. The system of claim 28, wherein a means for measuring the reactive hyperemia indicator comprises a means for assessing a change in arterial volume of a limb segment of the mammal.

30. The system of claim 29, wherein a means for assessing the change in arterial volume of the limb segment comprises:

a means for determining amplitudes of component pulse waves of detected volume pulse waves of the limb segment detected during a baseline period prior to applying the stimulus to determine a baseline arterial volume;

a means for determining amplitudes of component pulse waves of detected volume pulse waves of the limb segment detected during a time period after the stimulus has been applied to determine a post-stimulus arterial volume; and

a means for determining relative change in arterial volume of the limb segment based on the difference between the baseline arterial volume and the post-stimulus arterial volume.

31. The system of claim 30, wherein the component pulse wave is an early systolic component.

32. The system of claim 28, wherein a means for adjusting the reactive hyperemia indicator comprises a means for approximating a measure of reactive hyperemia based on brachial artery ultrasound imaging.

33. The system of claim 23, wherein the means for adjusting further comprises a means for using an algorithm to adjust the reactive hyperemia indicator based upon (i) a lean body mass of the mammal and (ii) at least one of a pulse pressure, a systolic blood pressure, a diastolic blood pressure, and a mean arterial pressure of the mammal.

34. The system of claim 33, wherein the pulse pressure, the systolic blood pressure, the diastolic blood pressure, and the mean arterial pressure are determined prior to measuring the reactive hyperemia indicator.

35. The system of claim 33, wherein the means for adjusting further comprises a means for using the algorithm to adjust the reactive hyperemia indicator based upon the pulse pressure and the mean arterial pressure, and wherein the pulse pressure and the mean arterial pressure are differentially weighted in the algorithm.

36. The system of claim 35, wherein the greater the lean body mass, the more the mean arterial pressure is weighted in the algorithm.

37. The system of claim 35, wherein the smaller the lean body mass, the more the pulse pressure is weighted in the algorithm.

38. The system of claim 35, wherein the algorithm comprises:

$$\text{AD-FMD}_U = \left[\left[\frac{\text{PWA}_{\text{MAX}} - \text{PWA}_{\text{PREOCC}}}{\text{PWA}_{\text{PREOCC}}} + 1 \right]^{1/2} - 1 \right] * [100/C]$$

PWA_{MAX}: Maximum post-occlusion pulse wave amplitude (PWA)
PWA_{PREOCC}: Median pre-occlusion PWA
C = 3.4

wherein AD-FMD_U comprises an unadjusted percentage of flow-mediated dilation as determined by ANGIODEFENDER technology.

39. The system of claim 33, wherein the means for adjusting further comprises a means for using the algorithm to adjust the reactive hyperemia indicator

based upon the ratio of systolic blood pressure to diastolic blood pressure and the mean arterial pressure, and wherein the ratio of systolic blood pressure to diastolic blood pressure and the mean arterial pressure are differentially weighted in the algorithm.

40. The system of claim 39, wherein the greater the lean body mass, the more the mean arterial pressure is weighted in the algorithm.

41. The system of claim 39, wherein the smaller the lean body mass, the more the ratio of systolic blood pressure to diastolic blood pressure is weighted in the algorithm.

42. The system of claim 39, wherein the algorithm comprises:

$$AD-FMD_U = \{[(FMD_1 + 1)^{0.5}] - 1\} * 100/C;$$

wherein $FMD_1 = \{[PWA_{max}/(PWA_{preocc})^d] - 1\} / PWA_{preocc}$, $C=3.4$, $d=1$, PWA_{max} = Maximum post-occlusion pulse wave amplitude (PWA), PWA_{preocc} = Median pre-occlusion PWA, and $AD-FMD_U$ comprises an unadjusted percentage of flow-mediated dilation as determined by ANGIODEFENDER technology.

43. The system of claim 23, wherein the applied stimulus comprises at least one of a mechanical stimulation, a thermal stimulation, a chemical stimulation, an electrical stimulation, a neurological stimulation, a mental stimulation, or a physical exercise stimulation.

44. The system of claim 23, wherein the applied stimulus comprises an inflated cuff disposed on a limb segment of the mammal, the inflated cuff imparting a supra-systolic pressure for a time period sufficient to induce reactive hyperemia upon release of the supra-systolic pressure.

45. A non-transitory machine-readable medium encoded with instructions, that when executed by one or more processors, cause the processor to carry out a process for assessing endothelial function in a mammal, the process comprising:

applying a stimulus to generate reactive hyperemia;
measuring a reactive hyperemia indicator;
adjusting the reactive hyperemia indicator based on an anthropomorphic or
demographic variable to arrive at an endothelial function indicator; and
communicating the endothelial function indicator to a clinician.




FIG. 1

2/17




FIG. 2




FIG. 3




FIG. 4

5/17




FIG. 5




FIG. 6

7/17




FIG. 7

8/17




FIG. 8b




FIG. 8a

9/17




FIG. 9

10/17




FIG. 10




FIG. 11




FIG. 12

13/17




FIG. 13

14/17




FIG. 14




FIG. 15

16/17




FIG. 16A

17/17




FIG. 16B

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2016/040800

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61B 5/02; A61B 5/00; A61B 5/022; A61B 5/024; A61B 5/026; A61B 5/145 (2016.01)

CPC - A61B 5/02; A61B 5/00; A61B 5/022; A61B 5/024; A61B 5/026; A61B 5/145 (2016.08)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC - A61B 5/00; A61B 5/02; A61B 5/022; A61B 5/024; A61B 5/026; A61B 5/145; G06F 19/00; G06G 7/00; G06G 7/60

CPC - A61B 5/00; A61B 5/02; A61B 5/022; A61B 5/024; A61B 5/026; A61B 5/145; G06F 19/00; G06G 7/00; G06G 7/60

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

USPC - 600/309; 600/490; 600/504; 703/9 (keyword delimited)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Orbit, Google Patents, Google Scholar

Search terms used: hyperemia, endothelial function, blood flow, stimulation, stimulate, method, assessment, determine

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2014/0194754 A1 (CORDEX SYSTEMS LLC) 10 July 2014 (10.07.2014) entire document	1-45
A	US 2008/0269574 A1 (MAO) 30 October 2008 (30.10.2008) entire document	1-45
A	US 2003/0065270 A1 (RAINES et al) 03 April 2003 (03.04.2003) entire document	1-45
A	WO 2013/138428 A1 (SIEMENS AKTIENGESellschaft) 19 September 2013 (19.09.2013) entire document	1-45
A	US 2012/0041735 A1 (TAYLOR) 16 February 2012 (16.02.2012) entire document	1-45



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

29 August 2016

Date of mailing of the international search report

23 SEP 2016

Name and mailing address of the ISA/

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Blaine R. Copenheaver

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774

专利名称(译)	评估内皮功能的系统和方法		
公开(公告)号	EP3316766A4	公开(公告)日	2019-01-30
申请号	EP2016818919	申请日	2016-07-01
[标]申请(专利权)人(译)	艾沃锐斯特基因有限公司		
申请(专利权)人(译)	EVERIST GENOMICS INC.		
[标]发明人	LENEHAN PETER F EVERIST THOMAS STEPHEN III		
发明人	LENEHAN, PETER F. EVERIST, THOMAS STEPHEN, III		
IPC分类号	A61B5/02 A61B5/00 A61B5/022 A61B5/024 A61B5/026 A61B5/145		
CPC分类号	A61B5/02007 A61B5/02055 A61B5/02116 A61B5/02141 A61B5/02225 A61B5/0537 A61B5/14542 A61B5/14551 A61B5/1495 A61B5/4836 A61B5/6824 A61B5/7239 A61B8/06 A61B8/0891 A61B8/488		
优先权	62/187793 2015-07-01 US		
其他公开文献	EP3316766A1		
外部链接	Espacenet		

摘要(译)

用于评估内皮功能的医学诊断系统和方法包括基于拟人和/或人口统计变量调整响应于刺激测量的反应性充血指标。调整后的反应性充血指标提供了更准确的内皮功能反映，并可传达给临床医生。